Arvinas (ARVN) Common Equity (2017 - 2026)
Arvinas' (ARVN) quarterly Common Equity came in at $386.8 million in Q1 2026, down 41.4% year-on-year from $660.1 million in Q1 2025, and down 10.86% quarter-over-quarter from $433.9 million in Q4 2025.
Arvinas (ARVN) Common Equity (2017 - 2026) Analysis & Trends
Arvinas' Common Equity history runs 10 years deep, the most recent figure standing at $386.8 million for Q1 2026.
- On a quarterly basis, Common Equity fell 41.4% year-over-year to $386.8 million in Q1 2026; TTM through Mar 2026 was $386.8 million, a 41.4% decrease from a year earlier, with the FY2025 full-year figure at $433.9 million, down 22.75% from the prior year.
- Common Equity retreated to $386.8 million in Q1 2026 per ARVN's latest filing, from $433.9 million in the prior quarter.
- Across five years, Common Equity topped out at $723.3 million in Q1 2022 and bottomed at $386.8 million in Q1 2026.
- The 5-year median for Common Equity is $586.0 million (2024), against an average of $569.7 million.
- Across the five-year window, Common Equity increased 29.47% in 2024 and plunged 41.4% in 2026, its largest moves.
- Year by year, Common Equity stood at $564.9 million in 2022, then rose by 16.83% to $660.0 million in 2023, then retreated by 14.89% to $561.7 million in 2024, then fell by 22.75% to $433.9 million in 2025, then dropped by 10.86% to $386.8 million in 2026.
- Per Business Quant, the three latest ARVN Common Equity figures stand at $386.8 million (Q1 2026), $433.9 million (Q4 2025), and $564.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -98.34 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 14.38 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 4.76 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.50 Bn |
| 10 | Arvinas | 512.64 Mn | -102.26 Mn | - | 386.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 386.80 Mn |
| Dec 31, 2025 | 433.90 Mn |
| Sep 30, 2025 | 564.40 Mn |
| Jun 30, 2025 | 609.30 Mn |
| Mar 31, 2025 | 660.10 Mn |
| Dec 31, 2024 | 561.70 Mn |
| Sep 30, 2024 | 586.00 Mn |
| Jun 30, 2024 | 600.20 Mn |
| Mar 31, 2024 | 609.70 Mn |
| Dec 31, 2023 | 660.00 Mn |
| Sep 30, 2023 | 457.20 Mn |
| Jun 30, 2023 | 463.60 Mn |
| Mar 31, 2023 | 511.00 Mn |
| Dec 31, 2022 | 564.90 Mn |
| Sep 30, 2022 | 621.50 Mn |
| Jun 30, 2022 | 670.60 Mn |
| Mar 31, 2022 | 723.30 Mn |
| Dec 31, 2021 | 781.70 Mn |
| Sep 30, 2021 | 817.70 Mn |
| Jun 30, 2021 | 582.90 Mn |